These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1132 related articles for article (PubMed ID: 21486284)

  • 21. Tauroursodeoxycholic Acid Improves Motor Symptoms in a Mouse Model of Parkinson's Disease.
    Rosa AI; Duarte-Silva S; Silva-Fernandes A; Nunes MJ; Carvalho AN; Rodrigues E; Gama MJ; Rodrigues CMP; Maciel P; Castro-Caldas M
    Mol Neurobiol; 2018 Dec; 55(12):9139-9155. PubMed ID: 29651747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP.
    Schober A
    Cell Tissue Res; 2004 Oct; 318(1):215-24. PubMed ID: 15503155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
    Emborg ME
    J Neurosci Methods; 2004 Oct; 139(2):121-43. PubMed ID: 15488225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Animal models of early-stage Parkinson's disease and acute dopamine deficiency to study compensatory neurodegenerative mechanisms.
    Grandi LC; Di Giovanni G; Galati S
    J Neurosci Methods; 2018 Oct; 308():205-218. PubMed ID: 30107207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications.
    Jenner P
    Neurology; 2003 Sep; 61(6 Suppl 3):S4-11. PubMed ID: 14504374
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
    Iravani MM; Costa S; Jackson MJ; Tel BC; Cannizzaro C; Pearce RK; Jenner P
    Eur J Neurosci; 2001 Feb; 13(3):597-608. PubMed ID: 11168568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse.
    Tronci E; Francardo V
    J Neural Transm (Vienna); 2018 Aug; 125(8):1137-1144. PubMed ID: 29242978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of neurotoxin- and pesticide-induced animal models of Parkinson's disease in the evaluation of new drug delivery systems.
    Casanova Y; Negro S; Barcia E
    Acta Pharm; 2022 Mar; 72(1):35-58. PubMed ID: 36651528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.
    Gerlach M; Riederer P
    J Neural Transm (Vienna); 1996; 103(8-9):987-1041. PubMed ID: 9013391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can adenosine A
    Kanda T; Jenner P
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S21-S27. PubMed ID: 33349576
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-apoptotic effect of modified Chunsimyeolda-tang, a traditional Korean herbal formula, on MPTP-induced neuronal cell death in a Parkinson's disease mouse model.
    Li H; Park G; Bae N; Kim J; Oh MS; Yang HO
    J Ethnopharmacol; 2015 Dec; 176():336-44. PubMed ID: 26593210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B; Crossman AR; Brotchie JM
    Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
    Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
    Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ondansetron, a highly selective 5-HT
    Kwan C; Frouni I; Bédard D; Hamadjida A; Huot P
    Eur J Pharmacol; 2020 Mar; 871():172914. PubMed ID: 31926127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
    J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model.
    Tasaki Y; Yamamoto J; Omura T; Sakaguchi T; Kimura N; Ohtaki K; Ono T; Suno M; Asari M; Ohkubo T; Noda T; Awaya T; Shimizu K; Matsubara K
    Neurosci Lett; 2012 Jul; 521(1):15-9. PubMed ID: 22617635
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of Parkinson's disease.
    Chen Y; Zhang DQ; Liao Z; Wang B; Gong S; Wang C; Zhang MZ; Wang GH; Cai H; Liao FF; Xu JP
    Mol Neurodegener; 2015 Mar; 10():4. PubMed ID: 26013581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New agents promote neuroprotection in Parkinson's disease models.
    Santos CM
    CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):410-8. PubMed ID: 22483311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future.
    Fox SH; Brotchie JM
    Prog Brain Res; 2010; 184():133-57. PubMed ID: 20887873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.